CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 651 - 660 of 666
Study Number Lead Group Study Title CIRB Study Status
10042 ETCTN A Phase II trial of AZD9291 (osimertinib) with or without bevacizumab in patients with EGFR mutation positive NSCLC and brain metastases Adult CIRB - Early Phase Emphasis Available to Open
10031 ETCTN A Phase 1 Study of PARP inhibitor olaparib and HSP90 inhibitor AT13387 for treatment of advanced solid tumors with expansion in patients with recurrent epithelial ovarian; fallopian tube; peritoneal cancer or recurrent triple-negative breast cancer Adult CIRB - Early Phase Emphasis Available to Open
10030 ETCTN A phase 1 study of blinatumomab in combination with checkpoint inhibitor(s) of PD-1 (nivolumab) or both PD-1 (nivolumab) and CTLA-4 (ipilimumab) in patients with poor-risk; relapsed or refractory CD19+ precursor B-lymphoblastic leukemia Adult CIRB - Early Phase Emphasis Available to Open
10026 ETCTN A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Adult CIRB - Early Phase Emphasis Available to Open
10021 ETCTN A Phase 2 Study of MEDI4736(durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC Adult CIRB - Early Phase Emphasis Available to Open
10020 ETCTN A Phase II Multiple-Arm; Open-Label; Randomized Study of PARP inhibition (veliparib; ABT-888) and Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) Either alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC) Adult CIRB - Early Phase Emphasis Available to Open
10017 ETCTN A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer Adult CIRB - Early Phase Emphasis Available to Open
10015 ETCTN A Non-Randomized; Open-Label; Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma Adult CIRB - Early Phase Emphasis Available to Open
10014 ETCTN A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies Adult CIRB - Early Phase Emphasis Available to Open
10013 ETCTN Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, with or without Atezolizumab in Triple Negative Breast Cancer (TNBC) Adult CIRB - Early Phase Emphasis Available to Open
Displaying 651 - 660 of 666